News | RSNA | December 07, 2022

A presentation during the Radiological Society of North America Scientific Session and Annual Meeting (RSNA 2022) featured IceCure Medical Ltd. and its minimally-invasive cryoablation technology, addressing Increasing interest among breast and interventional radiologists in performing breast tumor cryoablation.

A presentation during the Radiological Society of North America Scientific Session and Annual Meeting (RSNA 2022) featured IceCure Medical Ltd. and its minimally-invasive cryoablation technology, addressing Increasing interest among breast and interventional radiologists in performing breast tumor cryoablation.

Photo credit: IceCure Medical Ltd.


December 9, 2022 — A poster presentation during the Radiological Society of North America Scientific Session and Annual Meeting (RSNA 2022) featured IceCure Medical Ltd. and its minimally-invasive cryoablation technology. Addressing Increasing interest among breast and interventional radiologists in performing breast tumor cryoablation, Kenneth Tomkovich, MD, presented "To Freeze or Not To Freeze? That is the Question: Cryoablation for the Treatment of Breast Cancer.” Tomkovich was a Co-Primary investigator for IceCure's ICE3 clinical trial, and is a Diagnostic and Interventional Radiologist with Princeton Radiology, CentraState Medical Center, and Penn Princeton Medical Center in Princeton, New Jersey. Tomkovich presented interim data from the ICE3 clinical trial at RSNA 2021 with his presentation titled "Primary Treatment of Low Risk Breast Cancers Using Image-Guided Cryoablation: A 6 Year Update of the ICE3 Trial."

ICE3 is the largest controlled, multicenter clinical trial ever performed in the U.S. for liquid nitrogen-based cryoablation of small, low-risk, early-stage malignant breast tumors. Interim analysis submitted as part of IceCure’s filing a De Novo classification request with the FDA for marketing authorization of ProSense with Breakthrough Indication for early-stage, low-risk breast cancer patients at high risk to surgery, shows to date, there have been six cases of ipsilateral breast tumor recurrence (IBTR) out of 194 patients, or 3.09%. Final ICE3 5-year follow-up data is expected in the first half of 2024.

The Company was recently assigned a CPT Category III Code from the Centers for Medicare & Medicaid Services (CMS) for the its ProSense breast cancer cryoablation procedures, which is priced for coverage by the CMS at approximately $3,400 for the facility fee alone.

IceCure Medical Ltd. develops and markets ProSense, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.

For more information: icecure-medical.com

Find more RSNA22 coverage here 


Related Content

News | Artificial Intelligence

June 11, 2024 — A new study led by researchers at Emory AI.Health, published in the Journal of Computers in Medicine and ...

Time June 11, 2024
arrow
News | Breast Imaging

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
arrow
News | Radiopharmaceuticals and Tracers

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
arrow
News | Breast Density

June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower ...

Time June 06, 2024
arrow
News | Radiology Imaging

June 5, 2024 — RadiologyInfo.org, a leading source of medical imaging information for the general public, has introduced ...

Time June 05, 2024
arrow
News | Breast Imaging

June 4, 2024 — Using artificial intelligence (AI), breast radiologists in Denmark have improved breast cancer screening ...

Time June 04, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

May 31, 2024 — Low-level light therapy appears to affect healing in the brains of people who suffered significant brain ...

Time May 31, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
News | Lung Imaging

May 24, 2024 — Smokers who have small abnormalities on their CT scans that grow over time have a greater likelihood of ...

Time May 24, 2024
arrow
Subscribe Now